Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY15

[1]  P. Buchwald,et al.  CD40-targeting KGYY15 peptides do not efficiently block the CD40–CD40L interaction , 2019, Diabetologia.

[2]  Y. Takada,et al.  Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling , 2019, The Journal of Immunology.

[3]  Michael H. Olmstead,et al.  CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter] , 2019, Diabetologia.

[4]  Fa Liu,et al.  CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor , 2019, Diabetologia.

[5]  Minsoo Kim,et al.  LFA-1 in T Cell Migration and Differentiation , 2018, Front. Immunol..

[6]  Zhengfan Jiang,et al.  Manganese Increases the Sensitivity of the cGAS‐STING Pathway for Double‐Stranded DNA and Is Required for the Host Defense against DNA Viruses , 2018, Immunity.

[7]  M. Aschner,et al.  Manganese metabolism in humans. , 2018, Frontiers in bioscience.

[8]  N. Verma,et al.  Not Just an Adhesion Molecule: LFA-1 Contact Tunes the T Lymphocyte Program , 2017, The Journal of Immunology.

[9]  D. Wagner,et al.  CD40‐mediated signalling influences trafficking, T‐cell receptor expression, and T‐cell pathogenesis, in the NOD model of type 1 diabetes , 2017, Immunology.

[10]  D. Wagner,et al.  Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells , 2017, PloS one.

[11]  Dean P. Jones,et al.  Redox dynamics of manganese as a mitochondrial life-death switch. , 2017, Biochemical and biophysical research communications.

[12]  T. Mayadas,et al.  The many faces of Mac‐1 in autoimmune disease , 2016, Immunological reviews.

[13]  Souhad El Akoum,et al.  Interaction of CD154 with different receptors and its role in bidirectional signals , 2015, European journal of immunology.

[14]  Michael H. Olmstead,et al.  A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice , 2014, Diabetologia.

[15]  T. Schreiner,et al.  Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells , 2014, Journal of Neuroimmunology.

[16]  D. Wagner,et al.  CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression , 2013, Cellular and Molecular Immunology.

[17]  D. Wagner,et al.  Galectin-9 Controls CD40 Signaling through a Tim-3 Independent Mechanism and Redirects the Cytokine Profile of Pathogenic T Cells in Autoimmunity , 2012, PloS one.

[18]  A. Rajpal,et al.  Exploring the Dynamic Range of the Kinetic Exclusion Assay in Characterizing Antigen-Antibody Interactions , 2012, PloS one.

[19]  Jianfeng Chen,et al.  2012 Landes Bioscience. Do not distribute. The regulation of integrin function by divalent cations , 2012 .

[20]  S. Paik,et al.  Crystallographic and Mutational Analysis of the CD40-CD154 Complex and Its Implications for Receptor Activation* , 2011, The Journal of Biological Chemistry.

[21]  D. Wagner,et al.  CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. , 2010, Molecular immunology.

[22]  D. Wagner,et al.  The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells , 2010 .

[23]  P. Buchwald,et al.  Small-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interaction , 2009, Journal of Molecular Medicine.

[24]  P. Buchwald,et al.  Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects. , 2009, Biochemical pharmacology.

[25]  L. Tei,et al.  Inhibition of CD40–CD154 costimulatory pathway by a cyclic peptide targeting CD154 , 2009, Journal of Molecular Medicine.

[26]  D. Wagner,et al.  High Distribution of CD40 and TRAF2 in Th40 T Cell Rafts Leads to Preferential Survival of this Auto-Aggressive Population in Autoimmunity , 2008, PloS one.

[27]  P. Gottlieb,et al.  A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes. , 2007, Clinical immunology.

[28]  G. Bishop,et al.  A Costimulatory Function for T Cell CD401 , 2007, The Journal of Immunology.

[29]  S. Ito,et al.  Identification of three novel peptides that inhibit CD40–CD154 interaction , 2005, Modern rheumatology.

[30]  C. Whitacre,et al.  Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. , 2005, The journal of peptide research : official journal of the American Peptide Society.

[31]  Y. Shoenfeld,et al.  The Role of CD40–CD154 Interactions in Autoimmunity and the Benefit of Disrupting this Pathway , 2004, Autoimmunity.

[32]  D. Boumpas,et al.  Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients , 2004, Lupus.

[33]  D. Wagner,et al.  Peripheral CD4loCD40+ auto‐aggressive T cell expansion during insulin‐dependent diabetes mellitus , 2004, European journal of immunology.

[34]  O. Sartor,et al.  Suramin's Development: What Did we Learn? , 2002, Investigational New Drugs.

[35]  A. Schned,et al.  Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. , 2003, Arthritis and rheumatism.

[36]  K. Haskins,et al.  Cutting Edge: CD40-Induced Expression of Recombination Activating Gene (RAG) 1 and RAG2: A Mechanism for the Generation of Autoaggressive T Cells in the Periphery1 , 2003, The Journal of Immunology.

[37]  G. Illei,et al.  A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. , 2003, Arthritis and rheumatism.

[38]  K. Haskins,et al.  Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Miller,et al.  CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. , 2002, Journal of autoimmunity.

[40]  K. Okumura,et al.  Role of costimulatory molecules in autoimmunity. , 2000, Reviews in immunogenetics.

[41]  R. Tisch,et al.  CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. , 1997, Journal of immunology.

[42]  Wei Wei Wu,et al.  Monoclonal antibodies to murine CD40 define two distinct functional epitopes , 1994, European journal of immunology.

[43]  A. Aruffo,et al.  Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.

[44]  J. Bajorath,et al.  The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome , 1993, Cell.

[45]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.